Trade Coherus BioSciences - CHRS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.91 |
| Open | 1.91 |
| 1-Year Change | -75.35% |
| Day's Range | 1.91 - 2.03 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | 1.91 | -0.06 | -3.05% | 1.97 | 2.00 | 1.89 |
| Apr 24, 2024 | 2.00 | -0.15 | -6.98% | 2.15 | 2.19 | 2.00 |
| Apr 23, 2024 | 2.16 | 0.06 | 2.86% | 2.10 | 2.22 | 2.10 |
| Apr 22, 2024 | 2.16 | 0.10 | 4.85% | 2.06 | 2.16 | 2.02 |
| Apr 19, 2024 | 2.03 | 0.07 | 3.57% | 1.96 | 2.06 | 1.93 |
| Apr 18, 2024 | 1.97 | -0.14 | -6.64% | 2.11 | 2.16 | 1.97 |
| Apr 17, 2024 | 2.12 | -0.03 | -1.40% | 2.15 | 2.20 | 2.10 |
| Apr 16, 2024 | 2.13 | -0.02 | -0.93% | 2.15 | 2.16 | 2.10 |
| Apr 15, 2024 | 2.18 | -0.03 | -1.36% | 2.21 | 2.21 | 2.12 |
| Apr 12, 2024 | 2.21 | -0.15 | -6.36% | 2.36 | 2.39 | 2.18 |
| Apr 11, 2024 | 2.39 | -0.08 | -3.24% | 2.47 | 2.49 | 2.32 |
| Apr 10, 2024 | 2.42 | 0.12 | 5.22% | 2.30 | 2.43 | 2.30 |
| Apr 9, 2024 | 2.45 | -0.04 | -1.61% | 2.49 | 2.58 | 2.44 |
| Apr 8, 2024 | 2.49 | 0.06 | 2.47% | 2.43 | 2.52 | 2.41 |
| Apr 5, 2024 | 2.40 | 0.12 | 5.26% | 2.28 | 2.45 | 2.23 |
| Apr 4, 2024 | 2.31 | -0.08 | -3.35% | 2.39 | 2.42 | 2.28 |
| Apr 3, 2024 | 2.36 | 0.05 | 2.16% | 2.31 | 2.46 | 2.28 |
| Apr 2, 2024 | 2.33 | 0.04 | 1.75% | 2.29 | 2.35 | 2.25 |
| Apr 1, 2024 | 2.38 | 0.02 | 0.85% | 2.36 | 2.39 | 2.28 |
| Mar 28, 2024 | 2.36 | -0.04 | -1.67% | 2.40 | 2.49 | 2.34 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Coherus BioSciences Company profile
About Coherus Biosciences Inc
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. It operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. It is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Coherus Biosciences Inc revenues decreased 31% to $326.6M. Net loss totaled $287.1M vs. income of $132.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Research and development increase from $128.9M to $344.4M (expense), General and administrative increase of 20% to $138.1M (expense).
| Industry: | Bio Therapeutic Drugs |
C/O Dennis M. Lanfear
201 Redwood Shores Parkway, Suite 200
REDWOOD CITY
CALIFORNIA 94065
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com